For five thousand years, Panax ginseng has been the most prized medicinal root in East Asian medicine. Its name Panax comes from the Greek for all-healer. It has been the subject of more clinical trials than almost any other botanical. And in 2024, it was added to a European list of 117 substances for restriction.
This one requires careful, honest treatment — because ginseng does have a small adverse event profile and a set of drug interactions that responsible practitioners need to understand.
The NIH LiverTox database acknowledges that a small number of hepatotoxicity cases have been reported in association with ginseng use, typically appearing one to three months after starting the supplement. The cases are described as uncommon, involving a mixed hepatocellular pattern, and generally self-limiting. Some resolved on discontinuation without sequelae.
Beyond hepatotoxicity, Panax ginseng has documented pharmacokinetic interactions. The warfarin interaction is real and has been demonstrated in pharmacokinetic studies. The direction of the interaction is complex — both increasing and decreasing anticoagulant effect have been reported in different studies, suggesting the mechanism is not straightforward and warrants caution rather than simple predictability. Ginseng also interacts with hypoglycaemic agents its demonstrated blood glucose-lowering effects may potentiate antidiabetic medication, requiring monitoring in diabetic patients. Some ginsenosides show mild oestrogenic activity in vitro, which raises precautionary concern in patients with hormone-sensitive conditions such as oestrogen-receptor-positive breast cancer.
The safety evidence what systematic reviews actually show.
A 2017 systematic review specifically designed to evaluate the safety of Panax ginseng in randomised clinical trials, published in PMC, concluded that adverse events were mainly general symptoms: dyspepsia, hot flushes, insomnia, and that these were observed in both the ginseng and placebo groups with comparable frequency. This is the signature of a well-tolerated intervention at standard doses.
A systematic review by Vogler and colleagues, examining the complete RCT adverse event database for Panax ginseng monopreparations, concluded that P. ginseng monopreparations are rarely associated with adverse events or drug interactions. The umbrella review published in Frontiers in Pharmacology in 2023 confirmed: adverse events included gastrointestinal symptoms and potential bleeding concerns, but no serious adverse events were reported.
The Ginseng Abuse Syndrome dose context.
"Ginseng Abuse Syndrome" was described by Siegel in 1979 in people taking very high doses; 3 to 15 grams of ginseng root per day over extended periods. Symptoms included hypertension, insomnia, morning diarrhoea, and nervousness. This is a high-dose toxicity picture not seen at standard supplement doses of 100 to 400 milligrams of standardised ginseng extract per day. The distinction matters: this is not a concern at therapeutic doses, and the name "abuse syndrome" is a description of what happens when people take 10 to 40 times the recommended amount. It is not a reason to restrict access to standard preparations.
The hepatotoxicity picture
The hepatotoxicity case reports for ginseng are real. They are small in number — LiverTox describes the association as uncommon. The cases resolve on discontinuation. Causality attribution is complicated by the fact that many people who use ginseng also use other supplements or medications. The absolute case count is a fraction of the adverse event burden of paracetamol, ibuprofen, or SSRIs — none of which are under restriction.
The traditional use and consumption context.
Panax ginseng has been used in Korea, China, and Japan in traditional medicine for five thousand years. It is one of the best-studied and most widely consumed botanicals in the world. The Korean traditional medicine system, the Chinese pharmacopoeia, and the Japanese health system all have well-established frameworks for ginseng use. Against that consumption history, the adverse event signal is as small as it is possible to be while still being clinically visible.
What proportionate regulation looks like.
Practitioner screening for anticoagulant therapy, antidiabetic medication, and hormone-sensitive conditions. Dosing guidance that distinguishes between standardised extract and crude root. Product quality standards ensuring authentic Panax ginseng and accurate standardisation of ginsenoside content. This is the clinical management approach. It does not require prohibition.
Canada's Natural Health Products framework treats herbal medicines as a third regulatory category — distinct from both foods and conventional medicines. Products receive a Natural Product Number based on evidence of traditional use or clinical data, with product monographs specifying safe doses, contraindications, and drug interactions. This is what intelligent regulation looks like: it enables access, enforces quality, and provides the safety information currently prohibited on UK supplement labels under food law. The EU and UK should adopt this model not default to prohibition when their current regulatory frameworks cannot handle the complexity of herbal medicines.
Five thousand years of traditional medicine. A clean safety record at therapeutic doses. A drug interaction profile that is manageable through prescriber screening. And it is on a European restriction list.
The UK Government committed to align food supplement law with EU law under the SPS Agreement — without Parliament voting on it. That commitment is published at www.gov.uk/government/news/uk-eu-sps-agreement-legislation-in-scope .
Sign the petition. Respond to the EU consultation. Write to your MP at writetothem.com. Ask them: when did Parliament vote to restrict ginseng in the United Kingdom? The answer is: it has not. Demand that it does — before these restrictions take effect.
The right to access herbal medicine is not a fringe concern. It is a healthcare freedom. It is a constitutional question. And it requires your voice.
#RightToHeal #HerbalAccessNI #SaveOurSupplements
